The Committee on Medicines for People of the European Medicines Agency confirmed that an additional dose of COVID-19 vaccines produced by Pfizer or Moderna companies increases the ability to produce antibodies against coronavirus in immunocompromised people. A booster dose may be given at least 28 days after the second dose.
The European Medicines Agency’s Committee for Medicines for Human (CHMP) concluded that an additional dose of BioNTech / Pfizer or Moderna Covid-19 vaccine can be given to people with severely compromised immune systems at least 28 days after the second dose.
“Studies have shown that an additional dose of these vaccines increased the ability to produce antibodies against the virus that causes COVID-19 in immune-compromised organ transplant patients,” EMA said in a press release on Monday.
“While there is no direct evidence that the ability to produce antibodies in these patients protected against COVID-19, an additional dose is expected to increase protection in at least some patients. EMA will continue to monitor any emerging data on its effectiveness,” added . The agency also stressed that the new recommendations do not apply to people with a properly functioning immune system. In these cases, according to the EMA, booster doses may be considered at least 6 months after the second dose.
Main photo source: CAROLINE BREHMAN / PAP / EPA